VSTM: Verastem Inc

VSTM新闻

• 11:22 Mizuho lowers Verastem stock price target to $14 on dilution from financing
• 21:27 Verastem stock soars after KRAS inhibitor shows strong lung cancer results
• 20:32 GFH375 shows 68.8% response rate in non-small cell lung cancer study
• 22:40 Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates
• 08:40 Verastem CEO Paterson sells $7,738 in shares
• 21:55 Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates
• 14:00 Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
• 11:52 FDA grants fast track designation to Verastem’s pancreatic cancer drug
• 12:22 Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM)
• 20:19 Verastem stock rises after LGSOC treatment data published in medical journal
• 20:16 Verastem’s cancer drug shows 31% response rate in ovarian cancer trial
• 20:09 Avutometinib-defactinib combo shows strong results in LGSOC patients
• 15:16 Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
• 15:30 Verastem CEO Paterson sells $1.8k in shares
• 15:26 Verastem director Gagnon sells $1604 in shares
• 11:59 Cantor Fitzgerald reiterates overweight rating on Verastem stock
• 18:02 Meta and Biontech Lead Market Cap Stock Movers on Monday
• 16:49 Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May - Applied Digital (NASDAQ:APLD), Lyra Therapeutics (NASDAQ:LYRA)
• 16:41 What's Going On With Verastem Oncology Stock On Monday? - Verastem (NASDAQ:VSTM)
• 13:49 Verastem reports promising cancer drug trial results
• 13:37 TD Cowen maintains buy rating on Tempus AI stock after short report
• 11:45 Verastem Oncology to Present at the Jefferies Global Healthcare Conference
• 13:40 Verastem stock soars to 52-week high, hits $8.5
• 10:44 Tempus AI shareholders approve key proposals at annual meeting